Cooper Companies, Inc. (COO) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$53.27

Open

$54.37

Day range

$53.92 – $55.12

Volume

5.3M

About Cooper Companies, Inc.

Latest COO news

• The Cooper Companies (COO) Faces Near-Term Pressure from Slowing Contact Lens Demand
  Yahoo Finance · Sep 14, 2026

  The Cooper Companies is confronting a challenging stretch as demand growth in its core contact lens business decelerates, weighing on the near-term outlook for the medical device maker. CooperVision, which generates roughly 80 percent of the company's revenue, has benefited in recent years from a steady post-pandemic recovery and strong uptake of its daily disposable and myopia-control products. That momentum has cooled as the overall contact lens market shifts from the high-single-digit growth rates of the recovery period toward a more modest low-to-mid single-digit pace, leaving Cooper with less tailwind to offset competitive and macroeconomic pressures. Several factors are behind the slowdown. Consumers have grown more discretionary in their healthcare spending, and some eyecare practitioners and retailers have worked down inventory built up during supply-constrained periods, creating a destocking drag on shipments. Competition has also intensified in the daily disposable segment, where rivals including Alcon, Johnson & Johnson, and Bausch + Lomb continue to launch new silicone hydrogel lenses, pressuring pricing and market share. Even MiSight, Cooper's FDA-approved lens for slowing myopia progression in children, which had been a standout growth driver, has shown signs of more measured adoption as the company scales its salesforce and expands internationally. For investors, the deceleration raises questions about whether Cooper can sustain the premium valuation it has historically commanded as a consistent compounder in medtech. Shares have lagged at times when guidance has been trimmed, and any further softness in CooperVision's organic growth or margins could prompt analysts to lower estimates for the coming fiscal year. Peers reporting similar trends in vision care suggest the slowdown is largely a market-level phenomenon rather than a company-specific stumble, but that distinction offers limited comfort in the near term. Longer term, the structural case for contact lenses remains intact, supported by rising myopia prevalence, increased screen time, and aging populations, while CooperSurgical's fertility business offers a second growth engine if in-vitro fertilization volumes recover. Upcoming quarterly results and management commentary on fiscal-year guidance will be key catalysts, with investors looking for evidence that new product cycles, such as expanded MyDay offerings, can reaccelerate growth and stabilize sentiment around the stock.

• The Surprising Pockmarks On Cooper's Earnings That Caused Its Stock To Dive
  Yahoo Finance · Sep 10, 2026

  Cooper Companies experienced a sharp decline in its stock price following the release of its fiscal third-quarter earnings, which fell short of Wall Street's expectations. The medtech firm reported revenues that were lower than anticipated, leading to investor disappointment and a sell-off in its shares. This downturn highlights ongoing challenges in the medical technology sector, particularly as companies navigate post-pandemic market dynamics and shifting consumer demand. The earnings report revealed specific areas of concern, including weaker-than-expected performance in its contact lens division, which has been a significant driver of growth for the company. Analysts noted that supply chain disruptions and increased competition may have contributed to the disappointing results. As a result, Cooper's stock plummeted, reflecting broader market implications for investors in the medtech space, who may now reassess their positions in light of these earnings challenges. The situation underscores the volatility in the sector and the need for companies to adapt quickly to changing market conditions to maintain investor confidence.

• Ophthalmic Equipment Market Outlook Highlights Strategic Opportunities Across The Industry
  Market Outlook · Aug 20, 2026

  The ophthalmic equipment market is poised for significant growth, driven by advancements in technology and an increasing prevalence of eye-related disorders. According to recent analyses, the market is expected to expand at a compound annual growth rate (CAGR) of over 5% through the next five years. Key factors contributing to this growth include an aging population, rising awareness of eye health, and the introduction of innovative diagnostic and surgical devices. Strategic opportunities are emerging across various segments of the ophthalmic equipment industry, particularly in the areas of diagnostic imaging and surgical instruments. Companies are increasingly focusing on research and development to enhance product offerings, with a notable shift towards minimally invasive procedures that promise better patient outcomes. Additionally, the integration of artificial intelligence and telemedicine solutions is expected to revolutionize patient care and streamline operations within ophthalmic practices. Market players are advised to explore partnerships and collaborations to leverage technological advancements and expand their market reach. As competition intensifies, firms that can effectively navigate regulatory challenges and adapt to changing consumer preferences will likely gain a competitive edge. Overall, the outlook for the ophthalmic equipment market remains robust, presenting numerous avenues for growth and innovation in the coming years.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen